Blasco V, Leone M, Antonini F, Geissler A, Albanèse J, Martin C
Département d'Anesthésie et de Réanimation, CHU Nord, Assistance Publique-Hôpitaux de Marseille, 13915 Marseille Cedex 20, France.
Br J Anaesth. 2008 Apr;100(4):504-8. doi: 10.1093/bja/aen001. Epub 2008 Feb 6.
The renal effect of hydroxyethylstarch (HES) solutions remains controversial. We hypothesized that the use of HES with a mean molecular weight of 130 kDa would reduce renal dysfunctions in the recipients. Our study was aimed at comparing the effects of two fluid regimens (HES 130/0.4 or HES 200/0.6) used for the resuscitation of brain-dead donors on the rate of delayed graft function (DGF) and the serum creatinine levels post-transplantation.
This retrospective matched-paired study was conducted in an intensive care unit of a university hospital. Case-controls were matched at the donor patient level as follows: gender, BMI, duration of ICU stay, serum creatinine levels, vasopressor, and volume of colloids. The organ donation from 64 brain-dead donors resulted in 115 transplants.
The renal function was similar among all donors. The characteristics of the recipients, including the cold ischaemia time, were similar. The rate of DGF was 22% in the donors treated with HES 130/0.4, compared with 33% in those treated with HES 200/0.6 (P=0.27). The serum creatinine levels at 1 month were 133 (38) micromol litre(-1) when the donors had been treated with HES 130/0.4 and 172 (83) micromol litre(-1) when they were treated with HES 200/0.6 (P=0.005). A difference was found 1 yr after transplantation [128 (36) vs147 (43) micromol litre(-1), P=0.05].
Using a modern, third-generation, rapidly degradable HES preparation with a low degree of substitution seems to be associated with a better effect on the renal function of recipients.
羟乙基淀粉(HES)溶液对肾脏的影响仍存在争议。我们推测,使用平均分子量为130 kDa的HES可减少受者的肾功能障碍。我们的研究旨在比较用于脑死亡供体复苏的两种液体方案(HES 130/0.4或HES 200/0.6)对移植后延迟性移植物功能(DGF)发生率和血清肌酐水平的影响。
这项回顾性配对研究在一家大学医院的重症监护病房进行。病例对照在供体患者层面进行匹配,如下:性别、体重指数、重症监护病房住院时间、血清肌酐水平、血管加压药和胶体液量。64例脑死亡供体的器官捐献导致了115例移植。
所有供体的肾功能相似。受者的特征,包括冷缺血时间,也相似。接受HES 130/0.4治疗的供体中DGF发生率为22%,而接受HES 200/0.6治疗的供体中这一比例为33%(P = 0.27)。当供体接受HES 130/0.4治疗时,1个月时的血清肌酐水平为133(38)微摩尔/升,而接受HES 200/0.6治疗时为172(83)微摩尔/升(P = 0.005)。移植后1年发现有差异[128(36)对147(43)微摩尔/升,P = 0.05]。
使用具有低取代度的现代第三代快速降解HES制剂似乎对受者肾功能有更好的影响。